Previous Close | 36.57 |
Open | 36.51 |
Bid | 0.00 x 800 |
Ask | 38.48 x 800 |
Day's Range | 36.39 - 37.05 |
52 Week Range | 18.79 - 43.66 |
Volume | |
Avg. Volume | 340,420 |
Market Cap | 1.847B |
Beta (5Y Monthly) | 1.37 |
PE Ratio (TTM) | 117.55 |
EPS (TTM) | 0.31 |
Earnings Date | Apr 25, 2024 - Apr 29, 2024 |
Forward Dividend & Yield | 0.64 (1.76%) |
Ex-Dividend Date | Feb 21, 2024 |
1y Target Est | 37.33 |
Subscribe to Yahoo Finance Plus to view Fair Value for B
BioArctic AB's (publ) (Nasdaq: BIOA B) (Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1] of potential future sales for Leqembi, the world's first fully approved disease-modifying treatment for Alzheimer's disease. According to Eisai's simulation, Leqembi sales will reach JPY 290 billion for their financial year (FY) 2026, which ends in March 2027 and JPY 1.6 trillion in FY2032.
BRISTOL, Conn., March 05, 2024--Barnes Group Inc. (NYSE: B), a global provider of highly engineered products, differentiated industrial technologies, and innovative solutions, today announced the planned retirements of Chairman Thomas O. Barnes and Lead Independent Director Mylle H. Mangum, consistent with the Company’s corporate governance retirement policy, effective at the Company’s Annual Meeting of Stockholders in May 2024. Mr. Barnes will become Chairman Emeritus and continue to lead the B
Barnes Group ( NYSE:B ) Full Year 2023 Results Key Financial Results Revenue: US$1.45b (up 15% from FY 2022). Net...